227 related articles for article (PubMed ID: 18043486)
1. The role of xanthine oxidase in thiopurine metabolism: a case report.
Wong DR; Derijks LJ; den Dulk MO; Gemmeke EH; Hooymans PM
Ther Drug Monit; 2007 Dec; 29(6):845-8. PubMed ID: 18043486
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat as a novel option to optimize thiopurines' metabolism in patients with inadequate metabolite levels.
Doré M; Frenette AJ; Mansour AM; Troyanov Y; Bégin J
Ann Pharmacother; 2014 May; 48(5):648-51. PubMed ID: 24523395
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
4. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
5. Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease.
Kreijne JE; Seinen ML; Wilhelm AJ; Bouma G; Mulder CJ; van Bodegraven AA; de Boer NK
Ther Drug Monit; 2015 Dec; 37(6):797-804. PubMed ID: 25853923
[TBL] [Abstract][Full Text] [Related]
6. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
8. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
[TBL] [Abstract][Full Text] [Related]
10. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?
Sanderson J; Ansari A; Marinaki T; Duley J
Ann Clin Biochem; 2004 Jul; 41(Pt 4):294-302. PubMed ID: 15298741
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
[TBL] [Abstract][Full Text] [Related]
13. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus.
Askanase AD; Wallace DJ; Weisman MH; Tseng CE; Bernstein L; Belmont HM; Seidman E; Ishimori M; Izmirly PM; Buyon JP
J Rheumatol; 2009 Jan; 36(1):89-95. PubMed ID: 19040311
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
15. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease.
Ansari A; Aslam Z; De Sica A; Smith M; Gilshenan K; Fairbanks L; Marinaki A; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):749-57. PubMed ID: 18557988
[TBL] [Abstract][Full Text] [Related]
16. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study.
Seinen ML; van Asseldonk DP; de Boer NK; Losekoot N; Smid K; Mulder CJ; Bouma G; Peters GJ; van Bodegraven AA
J Crohns Colitis; 2013 Nov; 7(10):812-9. PubMed ID: 23317929
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
19. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
20. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
